Xlear says the move calls FTC’s authority to require clinical studies for non-pharmaceutical health products into question.

The brief requests the dismissal of FTC’s complaint against Xlear based on the Supreme Court’s recent decision in Loper Bright Enterprises v. Raimondo. 

As companies in the dietary supplement space seek to navigate the regulatory requirements around claims substantiation, understanding the terminology used is critical to ensuring the science meets the message.

Learn about the issue, how it impacts the natural products industry—and how industry members are taking action.

CRN said FTC's guidance misrepresents the state of the law with respect to advertising substantiation for dietary supplements and food. Take a look at the top concerns.